Agents for preventing and treating HIV and other viral infections

Patent metadata

Field	Value
Publication number	US-10030056-B2
Application number	US-201414787130-A
Country	US
Kind code	B2
Filing date	Apr 17, 2014
Priority date	Apr 30, 2013
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

An agent for preventing and/or treating HIV and other viral infections. The agent in particular comprises at least one peptide, including an amino acid sequence, which is suitable for preventing fibrils associated with Alzheimer's disease, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections.

First claim

The invention claimed is:

1. An agent, comprising at least one substance that is suitable for inhibiting formation of amyloid fibrils, which increase infection efficiency of human immunodeficiency virus (HIV), or for destroying the HIV, for application in a method to treat and/or prevent HIV infection and/or acquired immunodeficiency syndrome (AIDS) and/or a secondary disease of HIV infection, by using the substance to prevent formation of the amyloid fibrils,
wherein the substance comprises at least one peptide which
(i) includes an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, homologs of said peptides with an identity of at least 80%, and combinations thereof, and
(ii) is substantially or entirely composed of D-amino acids.

2. The agent according to claim 1 , wherein the agent has a binding affinity to the amyloid fibrils with a dissociation constant in the range of micromolar, submicromolar, or nanomolar.

3. A method for therapeutically treating and/or for preventing a viral infection and/or a secondary disease thereof in a human, comprising administering the agent according to claim 1 .

4. The method according to claim 3 , wherein the viral infection and/or a secondary disease is at least one of HIV and HAD.

5. The method according to claim 3 , comprising simultaneous therapeutic treatment and/or prevention of Alzheimer's disease and of HIV and/or HAD as the secondary disease and/or other secondary diseases.

6. A microbicidal gel, comprising at least one agent according to claim 1 .

7. The microbicidal gel according to claim 6 , wherein the agent is adapted for prevention of HIV and/or other viral infections and of HAD as a secondary disease and/or other secondary diseases.

8. The microbicidal gel according to claim 6 , wherein the microbicidal gel is adapted for use in a genital area.

9. A tablet, comprising at least one agent according to claim 1 .

10. The tablet according to claim 9 , wherein the agent is adapted for treatment of HIV and/or other viral infections and HAD as a secondary disease and/or other secondary diseases.

11. An injection solution or infusion solution, comprising at least one agent according to claim 1 .

12. The agent according to claim 1 , wherein the peptide is RD2 peptide comprising SEQ ID NO: 2.

13. The agent according to claim 1 , wherein the amino acid sequence is a homolog of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 10, with an identity of at least 80%.

Assignees

• Forschungszentrum Juelich Gmbh

Inventors

• Funke Susanne Aileen
• Willbold Dieter
• Schaal Heiner
• Widera Marek

Classifications

• A61P31/18

  for HIV · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title

• C07K14/4711

  Alzheimer's disease; Amyloid plaque core protein · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title